IRVINE, Calif., Sept. 19, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Rayonier Advanced Materials Inc. (“Rayonier” or the “Company”) (NYSE:RYAM). Investors who purchased or otherwise acquired Rayonier shares from October 29, 2014 through August 19, 2015, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the October 16, 2017 lead plaintiff motion deadline.
If you purchased Rayonier shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Rayonier issued materially false and misleading statements, and/or failed to disclose adverse information. Specifically, despite the Company’s claims during the Class Period that in 2015 Rayonier “will be able to maintain or increase [its] share of volume at each of [its] top 10 customers,” since 2013, one of its top three customers, Eastman Chemical Company (“Eastman”), had been informing Rayonier of its competitors’ pricing and had requested that Rayonier respond to declines in market pricing. This led to a protracted dispute between Rayonier and Eastman over the “meet and release” provision of their agreement.
On August 18, 2015, the Company told investors that the Company filed an action against Eastman regarding its “chemical cellulose specialty products contract with Eastman.” On August 19, 2015, Rayonier issued a press release further explaining the dispute with Eastman, stating that the language in the contract at issue involved the “meet or release” provisions of the agreement, which allowed Eastman to obtain “third party offers that meet the requirements of the Supply Agreement for similar cellulose specialties products, and would require [Rayonier] to either meet such price or release the volume, thereby allowing Eastman to purchase the volume from the third party.” The release also stated that on August 12, 2017, Eastman filed an action against the Company regarding the same “meet or release” provisions in their contract. When this news was announced, shares of Rayonier fell in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]


Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Italy Fines Apple €98.6 Million Over App Store Dominance
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 



